Affinity Asset Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
Other funds holding FDMT
Affinity Asset Advisors's FDMT Position: Q3 2026 in Review
Affinity Asset Advisors opened a new position in 4D Molecular Therapeutics (FDMT) in Q3 2026: 50,000 shares worth $716K. The stake represents 0.03% of the portfolio and ranks #117 among its holdings.
161 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.
- Affinity Asset Advisors held 50,000 shares of 4D Molecular Therapeutics worth $716K as of Q3 2026.
- 4D Molecular Therapeutics was a new Affinity Asset Advisors position in Q3 2026.
- 4D Molecular Therapeutics made up 0.03% of Affinity Asset Advisors's portfolio in Q3 2026, its #117 holding.
- 161 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.
Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.